-
Gilead’s HIV Combo on Hold, With No Impact on FDA's Pending Lenacapavir Decision
10 Jun 2025 18:13 GMT
… trials for Gilead’s investigational weekly HIV combo pill … treatment of people with multi-drug-resistant HIV and currently under FDA … trial is comparing the combo with Gilead’s approved HIV medicine … arise. Merck, for example, had trials of Isentress, launched …
-
HIV Diagnostics Market Projected To Hit USD 1.80 Billion By 2032, Driven By Rising Global Testing Rates And Technological Advancements | SNS Insider
10 May 2025 08:18 GMT
… Sunlenca (lenacapavir) Merck & Co., Inc.: Isentress (raltegravir) ViiV … rising number of diagnostic treatments carried out. Conversely, … accessibility and accuracy in HIV diagnostics, especially in … Market Outlook Rapid Medical Diagnostic Kits Market …
-
Lupin’s HIV generic gets FDA nod
09 May 2025 03:56 GMT
… S. Food and Drug Administration (U.S. FDA) for its … Abbreviated New Drug Application (ANDA) … is bioequivalent to Isentress HD tablets, marketed by Merck Sharp & … , for the treatment of human immunodeficiency virus (HIV-1) infection …
-
Lupin wins USFDA okay for HIV-1 drug Raltegravir
09 May 2025 07:40 GMT
… 39;s Abbreviated New Drug Application for Raltegravir Tablets … to Isentress HD Tablets, 600 mg of Merck Sharp … for the treatment of human immunodeficiency virus (HIV-1) … complex generics, biotechnology products, and active pharmaceutical ingredients. The …
-
Lupin receives US FDA approval for raltegravir tablets USP, 600 mg
08 May 2025 14:08 GMT
… the United States Food and Drug Administration (FDA) for its Abbreviated New … are bioequivalent to Isentress HD tablets, 600 mg of Merck Sharp … agents for the treatment of human immunodeficiency virus (HIV-1) infection in …
-
Merck Announces First-Quarter 2025 Financial Results
24 Apr 2025 10:47 GMT
… Drug Administration (FDA) granting Priority Review to Merck’s … as first-line treatment for adult … Trial
(Read Announcement)
Infectious Diseases
Merck Announced Positive Data From Phase 3 Trials … are provided below.
Pharmaceutical
BRIDION (sugammadex)
CAPVAXIVE …
-
HIV Drugs Market Outlook: Future Trends Indicate a US$ 47.5 Billion Industry by 2034 with a Shift Toward Single-dose Regimens | Report by TMR
18 Mar 2025 11:28 GMT
… Merck initiated clinical trials for its next-generation HIV treatment targeting drug … and ART medications.
Government … Merck & Co., Inc.
Isentress … HIV treatment
Teva Pharmaceutical Industries Ltd.
Generic ARVs, Lamivudine, Zidovudine
Growth in cos
HIV Drugs …
-
Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results
04 Feb 2025 13:04 GMT
… FDA Granted Priority Review to Merck’s Application for WELIREG for the Treatment … Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, … are provided below.
Pharmaceutical
BRIDION (sugammadex)
CAPVAXIVE …
-33
-28
Isentress/Isentress HD
111
89
…
-
HIV Treatment Information for Pregnant Women
30 Jan 2025 20:04 GMT
… and are virologically suppressed (HIV-1 RNA less than 50 … and are virologically suppressed (HIV-1 RNA less than 50 … available for the approved treatment dose of 600 mg … information available
Human Data
Isentress Label
Isentress HD
raltegravir 600 mg …
-
Second Woman May Be Cured of HIV After Stem Cell Transplant
01 Jan 2025 05:31 GMT
… HIV after receiving a stem cell transplant for cancer treatment … report presented at the HIV Drug Therapy meeting in Glasgow. … match, she also received medication to prevent graft-versus … she was taking raltegravir (Isentress) and tenofovir disoproxil fumarate…